- Home
- GSRF vs GLSI Comparison
GSRF vs GLSI Comparison
Compare GSRF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
SELL
Current Price
$15.21
Company Overview
Basic Information| Metric | GSRF | GLSI |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.8M | 254.7M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GSRF | GLSI |
|---|---|---|
| Price | $10.27 | $15.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 91.2K | ★ 121.2K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $184.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $7.78 |
| 52 Week High | $10.27 | $34.10 |
Technical Indicators
Market Signals| Indicator | GSRF | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 71.86 | 43.22 |
| Support Level | $10.15 | $14.57 |
| Resistance Level | N/A | $19.97 |
| Average True Range (ATR) | 0.00 | 1.47 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 75.00 | 25.05 |
Price Performance
Historical Comparison GSRF
GLSI
About GSRF GSR IV Acquisition Corp. Class A ordinary share
GSR IV Acquisition Corp is a blank check company.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.